Tests. Data tables by test.

Test	No. of studies	No. of participants
1 Cancerous versus benign or precancerous ‐ EUS‐FNA (cytology)	1	45
2 Cancerous versus benign or precancerous ‐ EUS‐FNA (CEA > 500 ng/mL)	1	24
3 Cancerous versus benign or precancerous ‐ PET	1	76
4 Cancerous versus benign ‐ EUS	2	133
5 Cancerous versus benign ‐ EUS‐FNA	3	147
6 Cancerous versus benign ‐ PET	3	99
7 Cancerous versus benign ‐ PET (SUVmax > 3.5)	1	80
8 Cancerous versus benign ‐ CT	2	123
9 Cancerous versus benign ‐ MRI	1	29
10 Precancerous or cancerous versus benign ‐ EUS	1	34
11 Precancerous or cancerous versus benign ‐ EUS‐FNA	3	52
12 Precancerous or cancerous versus benign ‐ EUS‐FNA (CEA > 50 ng/mL)	1	11
13 Precancerous or cancerous versus benign ‐ PET (SUVmax > 2.4)	1	32
14 Precancerous or cancerous versus benign ‐ CT	1	48
15 Precancerous or cancerous versus benign ‐ MRI	1	27
16 Cancerous (invasive carcinoma) versus precancerous (dysplasia) ‐ EUS	5	156
17 Cancerous (invasive carcinoma) versus precancerous (dysplasia) ‐ EUS‐FNA	3	158
18 Cancerous (invasive carcinoma) versus precancerous (dysplasia) ‐ EUS‐FNA (CEA > 200 ng/mL)	1	41
19 Cancerous (invasive carcinoma) versus precancerous (dysplasia) ‐ CT	6	326
20 Cancerous (invasive carcinoma) versus precancerous (dysplasia) ‐ MRI	1	32
21 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) ‐ EUS	4	196
22 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) ‐ EUS‐FNA	3	310
23 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) ‐ EUS‐FNA (CEA > 200 ng/mL)	3	160
24 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) ‐ EUS‐FNA (CA 19‐9 > 1000 U/mL)	1	41
25 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) ‐ EUS‐FNA (CEA > 692.8 ng/mL)	1	20
26 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) ‐ PET (SUVmax 2 to 2.5)	4	124
27 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) ‐ CT	3	139
28 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) ‐ MRI	3	189
29 Cancerous (invasive carcinoma) versus precancerous (low‐grade dysplasia) ‐ EUS	1	51
30 Cancerous (invasive carcinoma) versus precancerous (low‐grade dysplasia) ‐ CT	1	46
31 Precancerous or cancerous (intermediate‐ or high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐grade dysplasia) ‐ CT	3	106
32 Precancerous or cancerous (intermediate‐ or high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐grade dysplasia) ‐ MRI	2	71
33 Cancerous (high‐grade dysplasia or invasive carcinoma) versus precancerous (low‐ or intermediate‐grade dysplasia) or benign ‐ EUS	1	70
34 Cystic lesion subgroup analysis ‐ Cancerous versus benign ‐ EUS‐FNA	1	26
35 Cystic lesion subgroup analysis ‐ Cancerous versus benign ‐ PET	1	80
36 Cystic lesion subgroup analysis ‐ Precancerous or cancerous versus benign ‐ EUS‐FNA	2	34